The PARAGON-HF trial studied the effect of sacubitril/valsartan on NT-proBNP levels in patients with heart failure and preserved ejection fraction. The trial found that sacubitril/valsartan significantly reduced NT-proBNP levels compared to valsartan alone in patients with elevated levels of NT-proBNP at baseline. However, the treatment did not provide a significant reduction in cardiovascular death or hospitalization for heart failure compared to valsartan.

1. The PARAGON-HF Trial Pablo Toledo Frías
Effect Of Sacubitril/Valsartan On NT-proBNP
In Patients With Heart Failure
And Preserved Ejection Fraction:
The PARAGON-HF Trial
Dr. Jonathan W. Cunningham

2. The PARAGON-HF Trial Pablo Toledo Frías
Solomon SD, McMurray JJV, Anand IS et al. N Engl J Med. 2019 Oct 24;381(17):1609-1620

3. The PARAGON-HF Trial Pablo Toledo Frías

4. The PARAGON-HF Trial Pablo Toledo Frías

5. The PARAGON-HF Trial Pablo Toledo Frías

6. The PARAGON-HF Trial Pablo Toledo Frías

7. The PARAGON-HF Trial Pablo Toledo Frías

8. The PARAGON-HF Trial Pablo Toledo Frías